Navigation Links
Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
Date:2/23/2010

ts based on a number of factors, including risks and uncertainties inherent in the Company's business, including, but not limited to, the results and timing of the Company's discussions with the FDA; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; the Company's ability to retain key personnel and enter into strategic partnerships on favorable terms, or at all; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; the receipt and timing of any FDA and other required regulatory approvals, if any; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Report on Form 10-Q for the period ended September 30, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

SOU
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
2. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
3. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
4. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
5. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
6. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
8. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
9. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 Research and Markets ... "Global Medical Devices Packaging Market - By Packaging ... 2014 - 2020" report to their offering. ... is driven directly by its end use industry, i.e., ... the packaging of these devices so as to be ...
(Date:9/3/2015)... Research and Markets( http://www.researchandmarkets.com/research/fw4ctl/investigation ... Report on China,s Entecavir Market, 2010-2019" report to ... with hepatitis B virus (HBV) exceeds 100 million in ... suffering from chronic Hepatitis B. About 0.5 million Chinese ... cancer caused by chronic Hepatitis B, causing a loss ...
(Date:9/3/2015)... , Sep. 03, 2015 ... of the "Investigation Report on China,s Trastuzumab Market, ... by Genentech, trastuzumab was approved by FDA to be ... trade name of Herceptin, a major product of Roche. ... 6.56 billion around the world. After entering ...
Breaking Medicine Technology:Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 2Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 3Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 4Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 5Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 6Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 7Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 8China Entecavir Market Report 2010-2019 2Investigation Report on China's Trastuzumab (Genentech) Market, 2010-2019 2
(Date:9/3/2015)... ... September 03, 2015 , ... RealtyShares , the online ... institutional investors to real estate investment opportunities nationwide, today announced that it is ... investors and sponsoring real estate companies. , These products typically involve ...
(Date:9/3/2015)... NC (PRWEB) , ... September 03, 2015 , ... Girl’s ... 6:30pm-9:30pm at the beautiful Morning Glory Farm, 6205 Kate Road in Monroe, North Carolina. ... an event is a corporate or social function, Kate Clyde’s offers off-premise catering and ...
(Date:9/3/2015)... WA (PRWEB) , ... September ... ... of Washington, a leading provider of comprehensive eating disorder treatment for adults ... announced today that Ileana Calinoiu, MD has joined the medical treatment team. ...
(Date:9/3/2015)... ... 03, 2015 , ... According to an Oncology Nurse Advisor article ... patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated for relapses ... HPV infections, which have a high rate of success in treatment and elimination of ...
(Date:9/3/2015)... ... 2015 , ... Atlantic Information Services, Inc. (AIS) is pleased ... for a Rapidly Changing Marketplace.” In this Sept. 16 program, pharmacy benefit experts ... plan sponsors are adopting bold, innovative strategies to control soaring specialty pharmacy and ...
Breaking Medicine News(10 mins):Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2
... , , COLCHESTER, Vt., Aug. 31 ... and Health Sciences opened its Vermont Satellite Campus today, welcoming 70 ... Vermont, is home to the only pharmacy program in the state. ... four year program culminating in a Doctor of Pharmacy (Pharm.D.). The ...
... ... IPGDx, LLC; a Michigan medical technology development company, ... for prognosis based upon a noninvasive diagnostic test that objectively, accurately ... treatment is working (so it can be improved if possible). “The ...
... , ... Tarascon Publishing, a Jones and Bartlett Company, ... Ross I. Donaldson, MD and Timothy Horeczko, MD. The Tarascon Medical ... used in patient interviews with non-English speaking patients. An essential guide ...
... , MAASTRICHT, The Netherlands, Aug. 31 ... introducing the world,s first low-energy radiotherapy system with image-guidance and ... system is expected to make advanced care more affordable and ... , "This package is truly a unique ...
... BANNOCKBURN, Ill., Aug. 31 Omron Healthcare has announced a ... The achievement is part of a journey that began 36 years ... , , What has followed since 1973? The ... around the world. From PC compatible units which allow you to ...
... and improves survival, researchers say , SUNDAY, Aug. 30 ... was better than than clopidogrel (Plavix) in preventing new ... have had a heart attack, a new study finds. ... acute coronary syndrome," said lead researcher Dr. Robert A. ...
Cached Medicine News:Health News:Albany College of Pharmacy and Health Sciences Opens Vermont Satellite Campus 2Health News:Prognosis: A New Tool Now for Healthcare Reform and the Influenza Epidemic; ‘Cell Membranes' Tell the Story; PrognostiCheck Detects the Severity of Any Disease 2Health News:Prognosis: A New Tool Now for Healthcare Reform and the Influenza Epidemic; ‘Cell Membranes' Tell the Story; PrognostiCheck Detects the Severity of Any Disease 3Health News:Prognosis: A New Tool Now for Healthcare Reform and the Influenza Epidemic; ‘Cell Membranes' Tell the Story; PrognostiCheck Detects the Severity of Any Disease 4Health News:Tarascon Publishing Presents Essential Translation Resource for Healthcare Providers with Non-English Speaking Patients 2Health News:Tarascon Publishing Presents Essential Translation Resource for Healthcare Providers with Non-English Speaking Patients 3Health News:Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics 2Health News:Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics 3Health News:And the Beat Goes on 2Health News:New Anti-Clotting Drug Beats Plavix 2Health News:New Anti-Clotting Drug Beats Plavix 3Health News:New Anti-Clotting Drug Beats Plavix 4
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
PremierEdge™ Tunnel Knives....
Medicine Products: